Clinical trials: Huntington's Disease
Huntington Disease
TEsting METformin Against Cognitive Decline in HD
Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with Huntington's disease.
- Trial name
- TEMET (NCT04826692)
- Testing
- Metformin
- Where
- 9 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Huntington Disease
Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease
Huntington disease (HD, 1.3/10 000) is an autosomal dominant disease due to an abnormal expansion of CAG triplets in HTT gene. Several pathophysiological mechanisms have been evoked, including an alteration of the signaling…
- Trial name
- LCR-MH (NCT04012411)
- Testing
- Brain MRI, Lumbar Punction, Blood sample
- Where
- France
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Huntington's Disease
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.
- Trial name
- NCT03342053
- Testing
- RO7234292 (RG6042)
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Huntingtons Disease
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Study BP40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the PK of RO7234292 (RG6042) in plasma and CSF as well as the acute time course and recovery profile of CSF mHTT lowering in response…
- Trial name
- NCT04000594
- Testing
- RO7234292 (RG6042)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Huntington Disease
Riluzole in Huntington's Disease
Primary objective: The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington's Disease Rating…
- Trial name
- NCT00277602
- Testing
- Riluzole
- Volunteers
- 537 people
- Sponsor
- Sanofi
Huntington Disease
N- Homocysteinylated Huntingtin in Huntington's Disease
Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: 1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), 2.
- Trial name
- HO-HD (NCT05225051)
- Testing
- skin biopsy
- Volunteers
- 32 people
- Sponsor
- Central Hospital, Nancy, France
Huntington's Disease
Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease
OBJECTIVES: I. Correlate clinical outcome with cerebral glucose metabolism in patients with Huntington's disease (HD) and their at-risk relatives. II.
- Trial name
- NCT00004753
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Huntington Disease
Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience
The study hypothesis is that caregivers experience allows them to develop a lot of knowledge and know-how about behavioural problems in Huntington Disease and its consequences.
- Trial name
- HUNTEXPERT (NCT02218567)
- Testing
- questionnaire qualilty of life, psychological interview, psychological tests
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Huntington Disease
Gut Microbiomes in HD
The purpose of this study is to find out if there is a connection between the naturally occurring bacteria in our bodies and the progression of Huntington disease.
- Trial name
- NCT06448546
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Non Invasive Prenatal Diagnosis
NIPD on CFTC for Triplet Repeat Diseases
The purpose of this study is to develop and validate an analytical and clinical NIPD test for triplet repeat diseases by isolated circulating fetal trophoblastic cells (CFTC) analysis from maternal blood, searching for the…
- Trial name
- DIACCIMEX (NCT03087526)
- Testing
- Non invasive prenatal diagnosis
- Where
- 8 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Chorea, Huntington
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
- Trial name
- KINECT-HD (NCT04102579)
- Testing
- Valbenazine
- Where
- 46 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Neurocrine Biosciences
Huntington Disease, Hereditary Breast and Ovarian Cancer
Genetic Risk: Whether, When, and How to Tell Adolescents
This study is being conducted to learn more about family communication of genetic risk information. Semi-structured interviews lasting up to one hour will be conducted with three populations: parent/child pairs at risk for…
- Conditions
- Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer
- Trial name
- NCT03421327
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer's Disease, Huntington's Disease
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon.
- Trial name
- NCT00824590
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington's Disease
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
In individuals with Huntington's disease (HD), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fall rates.
- Trial name
- NCT01451463
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University
Huntingtons Disease
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)
- Trial name
- NCT03761849
- Testing
- RO7234292
- Where
- 96 sites in United States, Argentina and 16 more
- Volunteers
- 899 people
- Sponsor
- Hoffmann-La Roche
Huntington Disease
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626
This is a FIH (first-in-human) adaptive PET (Positron Emission Tomography) imaging study to explore the binding and kinetic properties of two potential mutant huntingtin (mHTT) radioligands; [¹¹C]CHDI-00485180-R and…
- Trial name
- NCT03810898
- Testing
- Radioligand [¹¹C]CHDI-00485180-R, Radioligand [¹¹C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Neurodegenerative Diseases
Exploring the Recovery Function of Sleep in Neurodegeneration
The overall objective of this study is to identify the best approach for assessing the recovery function of sleep in neurodegenerative diseases associated with abnormal protein aggregation with regard to the conception of future…
- Trial name
- RFSN (NCT05402488)
- Testing
- Auditory stimulation
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Huntington's Disease, Parkinson's Disease
Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon
The proposed study is a double-blind, placebo controlled pilot study of HD, PD, and DLB subjects with sleep disturbances. This study is designed to determine the effects of 4 weeks Ramelteon treatment on the sleep patterns of…
- Conditions
- Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies, Sleep Disorders
- Trial name
- NCT00907595
- Testing
- Ramelteon
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Apathy, Huntington's Disease
Apathy Cure Through Bupropion in Huntington's Disease
The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in…
- Trial name
- Action-HD (NCT01914965)
- Testing
- Bupropion
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Huntington's Disease
Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)
The purpose of this study is to evaluate the safety, tolerability and clinical impact of 15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay the groundwork for possible subsequent trials…
- Trial name
- NCT00212316
- Testing
- sodium phenylbutyrate
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester